(MedPage Today) -- A biosimilar version of the top-selling diabetes drug Lantus has won marketing authorization in the European Union, drugmakers Eli Lilly and Boehringer Ingelheim announced today. via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment